WATERTOWN, Mass.--(BUSINESS WIRE)--Nov. 1, 2016--
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that it plans to report its financial results for its fiscal fourth
quarter and year ended September 30, 2016 after the U.S. markets close
on November 21, 2016. Enanta management will host a conference call at
4:30 p.m. ET to discuss these results and provide an update on Enanta’s
research and development pipeline.
Conference Call and Webcast Information
To participate in the live conference call, please dial (855) 840-0595
in the U.S. or (518) 444-4814 for international callers. A replay of the
conference call will be available starting at approximately 7:30 p.m.
Eastern time on November 21, 2016, through 11:59 p.m. Eastern time on
November 25, 2016 by dialing (855) 859-2056 from the U.S. or (404)
537-3406 for international callers. The passcode for both the live call
and the replay is 9163079. A live audio webcast of the call and replay
can be accessed by visiting the “Calendar of Events” section on the
“Investors” page of Enanta’s website at www.enanta.com.
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs for viral
infections and liver diseases. Enanta’s research and development efforts
are currently focused on four disease targets: Hepatitis C Virus (HCV),
Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH) and
Respiratory Syncytial Virus (RSV).
Enanta has discovered novel protease inhibitors and NS5A inhibitors that
are members of the direct-acting-antiviral (DAA) inhibitor classes
designed for use against the hepatitis C virus (HCV). Enanta’s protease
inhibitors, developed through its collaboration with AbbVie, include
paritaprevir, which is contained in AbbVie’s marketed DAA regimens for
HCV, and glecaprevir (ABT-493), Enanta’s second protease inhibitor,
which AbbVie is developing in Phase 3 studies in combination with
pibrentasvir (ABT-530), AbbVie’s NS5A inhibitor. Enanta has also
discovered a cyclophilin inhibitor, EDP-494, a novel host-targeting
mechanism for HCV, which is now in a clinical proof-of-concept study in
HCV patients, and EDP-305, an FXR agonist product candidate for NASH,
currently in Phase 1 clinical development. In addition, Enanta has early
lead candidates for HBV and RSV in preclinical testing. Please visit www.enanta.com
for more information on our programs and pipeline.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161101005111/en/
Source: Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc.